Brief: I-Mab Strengthens Givastomig Intellectual Property Portfolio Through Acquisition Of Bridge Health

NovaBridge Biosciences

17/07/2025 12:57

I-Mab IMAB.O:

I-MAB STRENGTHENS GIVASTOMIG INTELLECTUAL PROPERTY PORTFOLIO THROUGH ACQUISITION OF BRIDGE HEALTH

I-MAB - BRIDGE HEALTH SHAREHOLDERS MAY RECEIVE UP TO $3.875 MILLION IN MILESTONES

I-MAB - TO PAY $1.8 MILLION UPFRONT AND $1.2 MILLION THROUGH 2027

Source text: ID:nGNXbyGVgR

Further company coverage: IMAB.O